Gastroenterology

The treatment represents the first approval for pediatric patients with functional constipation.

After they adjusted for manufacturer rebates to estimate net prices, the investigators fund HCV drug prices decreased by 31% from 2013-2020.

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

There were several risk factors identified, including abortion, hospitalization, past surgical procedure, dental extraction, delivery in hospital, injection in hospitals, and household contact with jaundice.

A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.

The results show a moderate certainty on the lack of effect across outcomes and 2 values and preferences studies found participants enjoyed specific counseling behavioral interventions.

Individuals who sought outpatient mental health and addiction services were generally younger, proportionately more female, more likely to have a psychiatric comorbidity, and more likely to have had their index alcohol-related hospitalization attributed to than to other diagnoses such as harmful alcohol use or alcoholic liver disease.

Hepatology experts discuss educating patients with hepatic encephalopathy on managing medications and supplements.

Kimberly A. Brown, MD, shares approaches to educating patients on management of hepatic encephalopathy and the importance of medication adherence and nutrition.

There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.

Drs Arun Jesudian and James William discuss approaches for proper discharge planning and transition of care and how this can reduce readmission for patients with hepatic encephalopathy.

A transplant hepatologist shares advice for emergency department physicians and clinicians to improve the diagnosis and treatment of hepatic encephalopathy.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

The prevalence rate was the highest in methadone clinics followed by correctional institutions, HIV clinics, and the surveillance program.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Expert hepatologists comment on primary care providers using rifaximin to manage and prevent episodes of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, highlight clinical trial data of rifaximin for the treatment of hepatic encephalopathy.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

James Williams, MS, DO, FACEP, provides insight on the importance of medication reconciliation when managing patients with hepatic encephalopathy.